AI assistant
Vaxcyte, Inc. — Director's Dealing 2025
Mar 4, 2025
31100_dirs_2025-03-03_767f3291-cd71-49c2-8639-56b09e6cfdc4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2025-02-27
Reporting Person: Wassil Jim (CHIEF OPERATING OFFICER)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-02-27 | Common Stock | A | 21726 | — | Acquired | 153421 | Direct |
| 2025-02-28 | Common Stock | A | 5649 | $73.02 | Acquired | 159070 | Direct |
| 2025-02-28 | Common Stock | F | 2869 | $73.02 | Disposed | 156201 | Direct |
| 2025-02-28 | Common Stock | F | 1270 | $73.02 | Disposed | 154931 | Direct |
| 2025-03-03 | Common Stock | M | 2638 | $2.42 | Acquired | 157569 | Direct |
| 2025-03-03 | Common Stock | M | 5362 | $5.35 | Acquired | 162931 | Direct |
| 2025-03-03 | Common Stock | S | 5915 | $73.071 | Disposed | 157016 | Direct |
| 2025-03-03 | Common Stock | S | 2085 | $73.837 | Disposed | 154931 | Direct |
| 2025-03-03 | Common Stock | F | 3015 | $72.10 | Disposed | 151916 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-02-27 | Stock Option (right to buy) | $74.22 | A | 72536 | Acquired | 2035-02-26 | Common Stock (72536) | Direct |
| 2025-03-03 | Stock Option (right to buy) | $2.42 | M | 2638 | Disposed | 2029-12-16 | Common Stock (2638) | Direct |
| 2025-03-03 | Stock Option (right to buy) | $5.35 | M | 5362 | Disposed | 2030-04-17 | Common Stock (5362) | Direct |
Footnotes
F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on September 7, 2025 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
F2: Represents RSUs issued in lieu of a cash bonus by election of the Reporting Person, such election available to all of Issuer's senior management. The RSUs are fully vested upon the date of grant.
F3: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.
F4: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024.
F5: The price reported is a weighted-average price. The shares were sold at prices ranging from $72.50 to $73.47. The reporting person will provide upon request to the SEC, the issuer or security holder of the
issuer, full information regarding the number of shares sold at each separate price.
F6: The price reported is a weighted-average price. The shares were sold at prices ranging from $73.51 to $74.41. The reporting person will provide upon request to the SEC, the issuer or security holder of the
issuer, full information regarding the number of shares sold at each separate price.
F7: 1/48 of shares subject to the option vest on March 27, 2025, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
F8: Option is fully vested and exercisable.